Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Viiv Healthcare UK (no. 4) Limited

Bristol-myers Squibb

Jie Chen

Sing-Yuen Sit

Nicholas A Meanwell

Alicia Regueiro-Ren

Jacob Swidorski

Yan Chen

Ny Sin

Zheng Liu

Brian Lee Venables

Carolyn Diane Dzierba

Junqing Guo

Amy C Hart

Yong-Jin Wu

Guanglin Luo

Richard A Hartz

William John Pitts

Jianliang Shi

John E Macor

Li-Qiang Sun

Steven H Spergel

Li Xu

Scott Hunter Watterson

Michael E Mertzman

Murugaiah Andappan Murugaiah Subbaiah

Michael G Yang

Zili Xiao

David Bertil Frennesson

Katherine S Takaki

Pierre Dextraze

Huan He

Ira B Dicker

Matthew Reiser Patton

Xirui Hu

Beata Nowicka-Sans

Paul Michael Scola

Piyasena Hewawasam

Andrew Charles Good

Graham Johnson

Stephen R Bertenshaw

Kin S Lam

Zhizhen Barbara Zheng

Hua Gong

Gene G Kinney

Xiangdong Alan Wang

Jason M Guernon

Alexandre L'Heureux

Jean-Paul Daris

Derek John Denhart

Marco Dodier

Steven Dworetzky

Carolyn A Weigelt

Li-Quang Sun

Yue-Zhong Shu

Daniel M Brown

Judith A Veitch

Michael C Mertzman

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Indazole carboxamides as kinase inhibitors

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1)

Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Aminotriazolopyridines as kinase inhibitors

Triazolopyridinyl compounds as kinase inhibitors

The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications. 

Aminopyrrolotriazines as kinase inhibitors

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.

C-3 and C-17 modified triterpenoids as HIV-1 inhibitors

Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX). 

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from Ccycloalkyl, Ccycloalkenyl, Cspirocycloalkyl, Cspirocycloalkenyl, Coxacycloalkyl, Cdioxacycloalkyl, Coxacycloalkenyl, Cdioxacycloalkenyl, Ccyclodialkenyl, Coxacyclodialkenyl, Coxaspirocycloalkyl and Coxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is &#x2014;Calkyl-halo. These compounds are useful for the treatment of HIV and AIDS.

Triterpenoids with HIV maturation inhibitory activity

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, azadecaline derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.

Azadecalin derivatives as inhibitors of human immunodeficiency virus replication

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I:  These compounds are useful for the treatment of HIV and AIDS.

C17-aryl substituted betulinic acid analogs

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I and II: These compounds are useful for the treatment of HIV and AIDS.

Extended betulinic acid analogs

Growing community of inventors

Madison, CT, United States of America

Jie Chen